Any current/future new fundraising through debt or equity?

The transcript from the earnings call on February 6, 2024, does not mention any current or planned fundraising activities through debt or equity. There is no discussion of new fund raises, capital market activities, or plans to issue shares or bonds. The company seems focused on operational performance, new projects like bromine derivatives, and acquisitions (e.g., Oren Hydrocarbon). Investments mentioned (e.g., INR20-30 crores for Oren Hydrocarbon revamp) appear to be funded internally or through existing resources. Management emphasizes conservative planning and cost efficiency but does not

Any current/future capex/capital investment/strategic investment?

Archean Chemical Industries plans to invest INR 20-30 crores for refurbishing and revamping the acquired Oren Hydrocarbons plants to make assets operational; this is not considered highly capital intensive. The company is commissioning a new bromine derivatives facility in Jagadia, Gujarat, with the first phase expected to start between Q1 and Q2 FY25, subject to regulatory clearances. Phase one of the derivatives plant is targeting around 70% capacity utilization in the first year, with phase two (flame retardants) expected to start revenues conservatively in FY26 with 60-70% utilization

Future growth expectations in sales/revenue/volumes?

Salt business volume expected to sustain around 4 million tons annually, with seasonal peaks (Q3/Q4) and slight monsoon dips. Bromine derivatives facility in Jagadia targeting revenues of INR 200-300 crore in FY25 from the first phase. Flame retardant segment (second phase) expected to start generating revenue conservatively from FY26 with initial utilization at 60-70%, ramping up thereafter. Overall EBITDA margin expected to remain in the 35-40% range, including derivative segment contributions. Bromine sales volume target around 28,000-29,000 tons in FY25, but a conservative approach is main

Future growth expectations in earnings/operating earnings/profits/EPS?

Bromine derivatives facility is expected to start revenues conservatively from FY26, beginning at 60-70% capacity utilization, ramping up thereafter. First phase of bromine derivatives targeting revenue between INR 200-300 crores in FY25. Overall EBITDA margin expected to remain in the 35-40% range even with the addition of derivative segments. Salt volumes are sustainable at over 4 million tons annually, supporting stable revenue from the industrial salt segment. SOP business is growing steadily, with expanding clientele and trials both domestically and overseas, expected meaningful g

Current/ Expected Orderbook/ Pending Orders?

Archean Chemical Industries has a backlog of almost 4,000 tons of bromine orders to be fulfilled. The company continues to perform on its long-term bromine contracts. There is ongoing demand from external customers; the company is optimistic about consuming 28,000-29,000 tons of elemental bromine in FY25. For the bromine derivatives business in phase one, customer trials and sampling began in January 2024, with positive feedback received. The company expects the bromine derivatives plant commissioning between Q1 and Q2 FY25. For flame retardants in phase two, around 90% of volumes are contract

IN US

Sale is live|00:00:00left today

Archean Chemical Industries LtdQ4 FY25Chemicals & Petrochemicals

Archean Chemical Industries Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹522P/E: 62.1Market Cap: ₹6.6K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Salt business volume expected to sustain around 4 million tons annually, with seasonal peaks (Q3/Q4) and slight monsoon dips.
→Bromine derivatives facility in Jagadia targeting revenues of INR 200-300 crore in FY25 from the first phase.
→Flame retardant segment (second phase) expected to start generating revenue conservatively from FY26 with initial utilization at 60-70%, ramping up thereafter.
→Overall EBITDA margin expected to remain in the 35-40% range, including derivative segment contributions.
→Bromine sales volume target around 28,000-29,000 tons in FY25, but a conservative approach is maintained.
→SOP segment expected to grow meaningfully in the latter part of next financial year with new client additions and trials.
→Domestic salt market involvement not planned; focus remains export-oriented with existing contracted volumes.

Margin guidance

Category 3

→Bromine derivatives facility is expected to start revenues conservatively from FY26, beginning at 60-70% capacity utilization, ramping up thereafter.
→First phase of bromine derivatives targeting revenue between INR 200-300 crores in FY25.
→Overall EBITDA margin expected to remain in the 35-40% range even with the addition of derivative segments.
→Salt volumes are sustainable at over 4 million tons annually, supporting stable revenue from the industrial salt segment.
→SOP business is growing steadily, with expanding clientele and trials both domestically and overseas, expected meaningful growth in the latter part of FY25.
→Acquisition of Oren Hydrocarbons expected to resume stable contributions, with potential peak revenues of around INR 430 crores historically, after plant refurbishment and ramp-up.
→The company adopts a conservative outlook, planning for worst-case scenarios while preparing to capitalize on favorable demand or pricing developments.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript from the earnings call on February 6, 2024, does not mention any current or planned fundraising activities through debt or equity.
→There is no discussion of new fund raises, capital market activities, or plans to issue shares or bonds.
→The company seems focused on operational performance, new projects like bromine derivatives, and acquisitions (e.g., Oren Hydrocarbon).
→Investments mentioned (e.g., INR20-30 crores for Oren Hydrocarbon revamp) appear to be funded internally or through existing resources.
→Management emphasizes conservative planning and cost efficiency but does not indicate the need for external fundraising at this time.

Order book

→Archean Chemical Industries has a backlog of almost 4,000 tons of bromine orders to be fulfilled.
→The company continues to perform on its long-term bromine contracts.
→There is ongoing demand from external customers; the company is optimistic about consuming 28,000-29,000 tons of elemental bromine in FY25.
→For the bromine derivatives business in phase one, customer trials and sampling began in January 2024, with positive feedback received.
→The company expects the bromine derivatives plant commissioning between Q1 and Q2 FY25.
→For flame retardants in phase two, around 90% of volumes are contracted, with revenue expected to start kicking in conservatively from FY26, initially at 60-70% capacity utilization.
→Salt volumes are largely contracted out, maintaining steady export orders with no current plans to increase domestic sales.

Capex plans

Yes

→Archean Chemical Industries plans to invest INR 20-30 crores for refurbishing and revamping the acquired Oren Hydrocarbons plants to make assets operational; this is not considered highly capital intensive.
→The company is commissioning a new bromine derivatives facility in Jagadia, Gujarat, with the first phase expected to start between Q1 and Q2 FY25, subject to regulatory clearances.
→Phase one of the derivatives plant is targeting around 70% capacity utilization in the first year, with phase two (flame retardants) expected to start revenues conservatively in FY26 with 60-70% utilization initially.
→The company has created a new subsidiary, SICS and Private Limited under NEUN INFRA Private Limited, with details and purpose to be shared once plans materialize.
→Continuous cost savings initiatives are ongoing, with some benefits anticipated in coming quarters, balancing cost efficiency and talent acquisition.

How does Archean Chemical Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Archean Chemical Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Archean Chemical Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio